Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lower Price For Tecentriq In ES-SCLC Secures Coverage In England

Executive Summary

Hot on the heels of recommending Roche’s drug for triple negative breast cancer, HTA body NICE today said the product should also be used for the first-line treatment of extensive-stage small-cell lung cancer.

You may also be interested in...



NICE Rejects Tecentriq For Small-Cell Lung Cancer In England

Roche’s Tecentriq has been rejected by health technology assessment body NICE for use in small-cell lung cancer on the National Health Service. The move follows an earlier knockback for the drug in PD L1-positive triple-negative breast cancer.

Pemaryze Wins Cost-Effectiveness Thumbs Up For Rare Bile Duct Cancer In England

Bavencio, Taltz, Cosentyx, and Opdivo plus Yervoy were this week also the subject of final recommendations from the health technology assessment body, NICE, on whether or not they should be used on the National Health Service for certain indications.

Frustration Over English Funding Rejection For Zytiga And A Win For Ledaga

Janssen and UK health technology assessment body NICE are being urged to sit down together and agree a suitable price for using Zytiga as a first-line treatment for advanced prostate cancer.

Topics

Related Companies

UsernamePublicRestriction

Register

PS142259

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel